^
    Back
    Association details:
    Biomarker:RET mutation
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:enbezotinib (TPX-0046) (Src kinase inhibitor, RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

    Excerpt:
    ...Evaluate the safety and tolerability of TPX-0046`Incidence of first cycle dose-limiting toxicities (DLTs) of TPX-0046`Determine the maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of TPX-0046`Define the Recommended Phase 2 Dose`Determine the preliminary efficacy by the ORR in defined cohorts of subjects with advanced/metastatic solid tumors harboring oncogenic RET fusions or mutations.`...
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Turning Point Therapeutics Press Release
    Title:

    Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046

    Published date:
    04/05/2021
    Excerpt:
    Turning Point Therapeutics, Inc....today reported initial clinical data from the ongoing Phase 1/2 SWORD-1 study of its RET inhibitor drug candidate, TPX-0046....A total of 21 patients with RET-altered NSCLC or MTC were treated with TPX-0046...Of 5 RET TKI-naïve patients, 4 showed tumor regressions of -42%, -37%, -23%, and -3%, including 2 patients dosed at 30 mg QD who achieved confirmed partial responses with duration of responses of 5.6 and 5.8+ months, respectively.